{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:54Z","timestamp":1791501774308,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRB CTN-2021-009 - 67245"],"award-info":[{"award-number":["HRB CTN-2021-009 - 67245"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is a rare, connective tissue disorder characterised by bone fragility, resulting in recurrent fractures and skeletal deformities. Extra-skeletal manifestations include dentinogenesis imperfecta, hearing abnormalities and lung disease. These co-morbidities combined with recurrent fractures can exert a significant impact on health-related quality of life (HR-QOL). It is important to assess HR-QOL throughout adulthood because the prevalence of some OI-specific complications increases with age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE and CENTRAL databases were searched on 2nd February 2022 to identify studies reporting quantitative assessments of HR-QOL in adults with OI. The primary endpoint was to determine the impact of an OI diagnosis\u00a0on adult\u2019s HR-QOL. Secondary endpoints were to (i) examine how frequently various HR-QOL assessment tools were used (ii) identify differences in HR-QOL between OI types and (iii) investigate the determinants of HR-QOL in adults with OI. Search results were exported to Endnote where two reviewers independently conducted title\/abstract and full-text reviews. Data from accepted studies were extracted into Microsoft Excel. A narrative synthesis was then undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review identified 17 studies with a total of 1,648 adults. The Short Form-36 (SF-36) was the most frequently reported HR-QOL assessment tool and was used in nine studies. Physical HR-QOL was reduced in adults with OI. Physical component scores (PCS) or individual physical domains of the SF-36 were lower in eight of nine studies. Mental component scores (MCS) were preserved in all six studies, however individual mental health domains of the SF-36 were reduced in some studies. The prevalence of anxiety\/depression was relatively low in adults with OI. Those with type III OI had lower physical and respiratory HR-QOL but preserved mental HR-QOL compared with type I. The prevalence of fatigue and pain was higher in adults with OI compared with reference populations. Age and cardio-pulmonary co-morbidities were associated with lower HR-QOL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OI in adulthood has a wide-ranging negative impact on HR-QOL. Physical and respiratory HR-QOL were lower, while the prevalence of pain and fatigue were higher than in reference populations. Mental HR-QOL was relatively preserved, although some deficits were identified. Age and cardio-pulmonary co-morbidities were associated with lower HR-QOL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02643-3","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T04:05:04Z","timestamp":1677038704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Systematic review of health related-quality of life in adults with osteogenesis imperfecta"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-9922","authenticated-orcid":false,"given":"Darran","family":"Mc Donald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Mc Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Martin-Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Mc Manus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"3","key":"2643_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11914-007-0023-z","volume":"5","author":"E Martin","year":"2007","unstructured":"Martin E, Shapiro JR. Osteogenesis imperfecta: epidemiology and pathophysiology. Curr Osteoporos Rep. 2007;5(3):91\u20137. https:\/\/doi.org\/10.1007\/s11914-007-0023-z.","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"2643_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316. https:\/\/doi.org\/10.1136\/jmg.16.2.101.","journal-title":"J Med Genet"},{"issue":"1","key":"2643_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/2040622317739538","volume":"9","author":"S Bacon","year":"2018","unstructured":"Bacon S, Crowley R. Developments in rare bone diseases and mineral disorders. Therap Adv Chronic Dis. 2018;9(1):51\u201360. https:\/\/doi.org\/10.1177\/2040622317739538.","journal-title":"Therap Adv Chronic Dis"},{"issue":"1","key":"2643_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ejhg.2011.141","volume":"20","author":"FS van Dijk","year":"2012","unstructured":"van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, Symoens S, Sistermans EA, Pals G. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet EJHG. 2012;20(1):11\u20139. https:\/\/doi.org\/10.1038\/ejhg.2011.141.","journal-title":"Eur J Hum Genet EJHG"},{"key":"2643_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bone.2017.02.004","volume":"102","author":"J Lim","year":"2017","unstructured":"Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone. 2017;102:40\u20139. https:\/\/doi.org\/10.1016\/j.bone.2017.02.004.","journal-title":"Bone"},{"issue":"6","key":"2643_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jped.2014.05.003","volume":"90","author":"ER Valadares","year":"2014","unstructured":"Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B. What is new in genetics and osteogenesis imperfecta classification? Jornal de pediatria. 2014;90(6):536\u201341. https:\/\/doi.org\/10.1016\/j.jped.2014.05.003.","journal-title":"Jornal de pediatria"},{"issue":"4","key":"2643_CR7","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/EJE-20-0299","volume":"183","author":"R Marom","year":"2020","unstructured":"Marom R, Rabenhorst BM, Morello R. Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol. 2020;183(4):R95\u2013106. https:\/\/doi.org\/10.1530\/EJE-20-0299.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2643_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164A","author":"FS Van Dijk","year":"2014","unstructured":"Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470\u201381. https:\/\/doi.org\/10.1002\/ajmg.a.36545.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2643_CR9","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1080\/07853890.2021.1980819","volume":"53","author":"S Storoni","year":"2021","unstructured":"Storoni S, Treurniet S, Micha D, Celli M, Bugiani M, van den Aardweg JG, Eekhoff E. Pathophysiology of respiratory failure in patients with osteogenesis imperfecta: a systematic review. Ann Med. 2021;53(1):1676\u201387. https:\/\/doi.org\/10.1080\/07853890.2021.1980819.","journal-title":"Ann Med"},{"key":"2643_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","volume":"71\u201372","author":"R Morello","year":"2018","unstructured":"Morello R. Osteogenesis imperfecta and therapeutics. Matrix Biol J Int Soc Matrix Biol. 2018;71\u201372:294\u2013312. https:\/\/doi.org\/10.1016\/j.matbio.2018.03.010.","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"2643_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JMDH.S113483","volume":"10","author":"C Marr","year":"2017","unstructured":"Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc. 2017;10:145\u201355. https:\/\/doi.org\/10.2147\/JMDH.S113483.","journal-title":"J Multidiscip Healthc"},{"issue":"7","key":"2643_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","volume":"34","author":"M Karimi","year":"2016","unstructured":"Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34(7):645\u20139. https:\/\/doi.org\/10.1007\/s40273-016-0389-9.","journal-title":"Pharmacoeconomics"},{"key":"2643_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4137\/HSI.S11093","volume":"6","author":"T Weldring","year":"2013","unstructured":"Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61\u20138. https:\/\/doi.org\/10.4137\/HSI.S11093.","journal-title":"Health Serv Insights"},{"issue":"14","key":"2643_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","volume":"32","author":"G Kotronoulas","year":"2014","unstructured":"Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, MacGillivray S. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480\u2013501. https:\/\/doi.org\/10.1200\/JCO.2013.53.5948.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2643_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00431-006-0399-2","volume":"166","author":"DH Kok","year":"2007","unstructured":"Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein RM, Engelbert RH. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr. 2007;166(11):1155\u201361. https:\/\/doi.org\/10.1007\/s00431-006-0399-2.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2643_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25(6):786\u201391. https:\/\/doi.org\/10.1097\/01.bpo.0000176162.78980.ed.","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"2643_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpeds.2007.06.029","volume":"152","author":"M Van Brussel","year":"2008","unstructured":"Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net J, Helders PJ, Engelbert RH. Physical training in children with osteogenesis imperfecta. J Pediatr. 2008;152(1):111-116.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2007.06.029.","journal-title":"J Pediatr"},{"issue":"1","key":"2643_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajmg.a.37377","volume":"170A","author":"N Dahan-Oliel","year":"2016","unstructured":"Dahan-Oliel N, Oliel S, Tsimicalis A, Montpetit K, Rauch F, Dogba MJ. Quality of life in osteogenesis imperfecta: a mixed-methods systematic review. Am J Med Genet A. 2016;170A(1):62\u201376. https:\/\/doi.org\/10.1002\/ajmg.a.37377.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2643_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"issue":"1","key":"2643_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13023-020-01493-7","volume":"15","author":"A Atalaia","year":"2020","unstructured":"Atalaia A, Thompson R, Corvo A, Carmody L, Piscia D, Matalonga L, Macaya A, Lochmuller A, Fontaine B, Zurek B, et al. A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome. Orphanet J Rare Disorders. 2020;15(1):206. https:\/\/doi.org\/10.1186\/s13023-020-01493-7.","journal-title":"Orphanet J Rare Disorders"},{"issue":"24","key":"2643_CR21","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware","year":"2000","unstructured":"Ware JE. SF-36 health survey update. Spine. 2000;25(24):3130\u20139. https:\/\/doi.org\/10.1097\/00007632-200012150-00008.","journal-title":"Spine"},{"key":"2643_CR22","unstructured":"Health NIo. National heart, lung and blood Institute quality assessment tool for observational cohort and cross-sectional studies. 2014."},{"issue":"1","key":"2643_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","volume":"11","author":"L Forestier-Zhang","year":"2016","unstructured":"Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C, Eastell R, Wordsworth P, Javaid MK, Pinedo-Villanueva R. Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis. 2016;11(1):160. https:\/\/doi.org\/10.1186\/s13023-016-0538-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2643_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/joor.13114","volume":"48","author":"H Gj\u00f8rup","year":"2021","unstructured":"Gj\u00f8rup H, Beck-Nielsen SS, Hald JD, Haubek D. Oral health-related quality of life in X-linked hypophosphataemia and osteogenesis imperfecta. J Oral Rehabil. 2021;48(2):160\u20138. https:\/\/doi.org\/10.1111\/joor.13114.","journal-title":"J Oral Rehabil"},{"issue":"1","key":"2643_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12891-017-1922-5","volume":"19","author":"H Arponen","year":"2018","unstructured":"Arponen H, Waltimo-Sir\u00e9n J, Valta H, M\u00e4kitie O. Fatigue and disturbances of sleep in patients with osteogenesis imperfecta-a cross-sectional questionnaire study. BMC Musculoskelet Disord. 2018;19(1):3. https:\/\/doi.org\/10.1186\/s12891-017-1922-5.","journal-title":"BMC Musculoskelet Disord"},{"key":"2643_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2018.05.021","volume":"113","author":"AG Feehan","year":"2018","unstructured":"Feehan AG, Zacharin MR, Lim AS, Simm PJ. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood. Bone. 2018;113:137\u201343. https:\/\/doi.org\/10.1016\/j.bone.2018.05.021.","journal-title":"Bone"},{"issue":"16","key":"2643_CR27","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/00007632-199908150-00008","volume":"24","author":"RF Widmann","year":"1999","unstructured":"Widmann RF, Bitan FD, Laplaza FJ, Burke SW, DiMaio MF, Schneider R. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine. 1999;24(16):1673\u20138. https:\/\/doi.org\/10.1097\/00007632-199908150-00008.","journal-title":"Spine"},{"issue":"1","key":"2643_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s002640100292","volume":"26","author":"RF Widmann","year":"2002","unstructured":"Widmann RF, Laplaza FJ, Bitan FD, Brooks CE, Root L. Quality of life in osteogenesis imperfecta. Int Orthop. 2002;26(1):3\u20136. https:\/\/doi.org\/10.1007\/s002640100292.","journal-title":"Int Orthop"},{"issue":"1","key":"2643_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00774-019-01033-9","volume":"38","author":"M Matsushita","year":"2020","unstructured":"Matsushita M, Mishima K, Yamashita S, Haga N, Fujiwara S, Ozono K, Kubota T, Kitaoka T, Ishiguro N, Kitoh H. Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta. J Bone Miner Metab. 2020;38(1):109\u201316. https:\/\/doi.org\/10.1007\/s00774-019-01033-9.","journal-title":"J Bone Miner Metab"},{"issue":"21","key":"2643_CR30","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2106\/JBJS.J.01893","volume":"93","author":"N Nicolaou","year":"2011","unstructured":"Nicolaou N, Bowe JD, Wilkinson JM, Fernandes JA, Bell MJ. Use of the Sheffield telescopic intramedullary rod system for the management of osteogenesis imperfecta: clinical outcomes at an average follow-up of nineteen years. J Bone Joint Surg. 2011;93(21):1994\u20132000. https:\/\/doi.org\/10.2106\/JBJS.J.01893.","journal-title":"J Bone Joint Surg"},{"issue":"5","key":"2643_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00223-017-0301-4","volume":"101","author":"JD Hald","year":"2017","unstructured":"Hald JD, Folkestad L, Harsl\u00f8f T, Brixen K, Langdahl B. Health-related quality of life in adults with osteogenesis imperfecta. Calcif Tissue Int. 2017;101(5):473\u20138. https:\/\/doi.org\/10.1007\/s00223-017-0301-4.","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2643_CR32","doi-asserted-by":"publisher","first-page":"e10416","DOI":"10.1002\/jbm4.10416","volume":"4","author":"K Gooijer","year":"2020","unstructured":"Gooijer K, Harsevoort A, van Dijk FS, Withaar HR, Janus G, Franken A. A baseline measurement of quality of life in 322 adults with osteogenesis imperfecta. JBMR Plus. 2020;4(12):e10416. https:\/\/doi.org\/10.1002\/jbm4.10416.","journal-title":"JBMR Plus"},{"issue":"4","key":"2643_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/pri.1546","volume":"18","author":"V Balkefors","year":"2013","unstructured":"Balkefors V, Mattsson E, Pernow Y, S\u00e4\u00e4f M. Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. Physiother Res Int. 2013;18(4):203\u201311. https:\/\/doi.org\/10.1002\/pri.1546.","journal-title":"Physiother Res Int"},{"issue":"12","key":"2643_CR34","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1097\/CORR.0000000000001400","volume":"478","author":"SI Khan","year":"2020","unstructured":"Khan SI, Yonko EA, Carter EM, Dyer D, Sandhaus RA, Raggio CL. Cardiopulmonary status in adults with osteogenesis imperfecta: intrinsic lung disease may contribute more than scoliosis. Clin Orthop Relat Res. 2020;478(12):2833\u201343. https:\/\/doi.org\/10.1097\/CORR.0000000000001400.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"2643_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00198-020-05537-3","volume":"32","author":"G Orlando","year":"2021","unstructured":"Orlando G, Pinedo-Villanueva R, Reeves ND, Javaid MK, Ireland A. Physical function in UK adults with osteogenesis imperfecta: a cross-sectional analysis of the RUDY study. Osteoporos Int. 2021;32(1):157\u201364. https:\/\/doi.org\/10.1007\/s00198-020-05537-3.","journal-title":"Osteoporos Int"},{"issue":"6","key":"2643_CR36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/cge.13939","volume":"99","author":"CN Murali","year":"2021","unstructured":"Murali CN, Slater B, Musaad S, Cuthbertson D, Nguyen D, Turner A, Azamian M, Tosi L, Rauch F, Sutton VR, Lee B, Nagamani S. Health-related quality of life in adults with osteogenesis imperfecta. Clin Genet. 2021;99(6):772\u20139. https:\/\/doi.org\/10.1111\/cge.13939.","journal-title":"Clin Genet"},{"issue":"1","key":"2643_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11657-020-00818-0","volume":"15","author":"EA Yonko","year":"2020","unstructured":"Yonko EA, Emanuel JS, Carter EM, Sandhaus RA, Raggio CL. Respiratory impairment impacts QOL in osteogenesis imperfecta independent of skeletal abnormalities. Arch Osteoporos. 2020;15(1):153. https:\/\/doi.org\/10.1007\/s11657-020-00818-0.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2643_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-019-1004-x","volume":"14","author":"LL Tosi","year":"2019","unstructured":"Tosi LL, Floor MK, Dollar CM, Gillies AP, Hart TS, Cuthbertson DD, Sutton VR, Krischer JP. Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study. Orphanet J Rare Dis. 2019;14(1):23. https:\/\/doi.org\/10.1186\/s13023-019-1004-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2643_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12891-019-3000-7","volume":"21","author":"A Harsevoort","year":"2020","unstructured":"Harsevoort A, Gooijer K, van Dijk FS, van der Grijn D, Franken A, Dommisse A, Janus G. Fatigue in adults with osteogenesis imperfecta. BMC Musculoskelet Disord. 2020;21(1):6. https:\/\/doi.org\/10.1186\/s12891-019-3000-7.","journal-title":"BMC Musculoskelet Disord"},{"key":"2643_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12931-016-0356-1","volume":"17","author":"AL Martin","year":"2016","unstructured":"Martin AL, Marvel J, Fahrbach K, Cadarette SM, Wilcox TK, Donohue JF. The association of lung function and St. George\u2019s respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respir Res. 2016;17:40. https:\/\/doi.org\/10.1186\/s12931-016-0356-1.","journal-title":"Respir Res"},{"issue":"1","key":"2643_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-021-01682-y","volume":"16","author":"W Nijhuis","year":"2021","unstructured":"Nijhuis W, Franken A, Ayers K, Damas C, Folkestad L, Forlino A, Fraschini P, Hill C, Janus G, Kruse R, Lande Wekre L, Michiels L, Montpetit K, Panzeri L, Porquet-Bordes V, Rauch F, Sakkers R, Salles JP, Semler O, Sun J, Verhoef M. A standard set of outcome measures for the comprehensive assessment of osteogenesis imperfecta. Orphanet J Rare Dis. 2021;16(1):140. https:\/\/doi.org\/10.1186\/s13023-021-01682-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2643_CR42","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00198-005-1905-5","volume":"16","author":"FE McKiernan","year":"2005","unstructured":"McKiernan FE. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int. 2005;16(12):1698\u2013702. https:\/\/doi.org\/10.1007\/s00198-005-1905-5.","journal-title":"Osteoporos Int"},{"issue":"11","key":"2643_CR43","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.cjca.2015.04.016","volume":"31","author":"Z Radunovic","year":"2015","unstructured":"Radunovic Z, Steine K. Prevalence of cardiovascular disease and cardiac symptoms: left and right ventricular function in adults with osteogenesis imperfecta. Can J Cardiol. 2015;31(11):1386\u201392. https:\/\/doi.org\/10.1016\/j.cjca.2015.04.016.","journal-title":"Can J Cardiol"},{"issue":"3","key":"2643_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ahj.2010.11.006","volume":"161","author":"Z Radunovic","year":"2011","unstructured":"Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J. 2011;161(3):523\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2010.11.006.","journal-title":"Am Heart J"},{"issue":"4","key":"2643_CR45","first-page":"B5454","volume":"65","author":"L Folkestad","year":"2018","unstructured":"Folkestad L. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark. Dan Med J. 2018;65(4):B5454.","journal-title":"Dan Med J"},{"issue":"8","key":"2643_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/jcp.49.8.627","volume":"49","author":"SJ McAllion","year":"1996","unstructured":"McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996;49(8):627\u201330. https:\/\/doi.org\/10.1136\/jcp.49.8.627.","journal-title":"J Clin Pathol"},{"issue":"6","key":"2643_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00431-018-3127-9","volume":"177","author":"A Tsimicalis","year":"2018","unstructured":"Tsimicalis A, Boitor M, Ferland CE, Rauch F, Le May S, Carrier JI, Ngheim T, Bilodeau C. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle. Eur J Pediatr. 2018;177(6):891\u2013902. https:\/\/doi.org\/10.1007\/s00431-018-3127-9.","journal-title":"Eur J Pediatr"},{"key":"2643_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/121054","author":"MC Scheper","year":"2013","unstructured":"Scheper MC, Engelbert RH, Rameckers EA, Verbunt J, Remvig L, Juul-Kristensen B. Children with generalised joint hypermobility and musculoskeletal complaints: state of the art on diagnostics, clinical characteristics, and treatment. BioMed Res Int. 2013. https:\/\/doi.org\/10.1155\/2013\/121054.","journal-title":"BioMed Res Int"},{"issue":"1","key":"2643_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpeds.2007.06.029","volume":"152","author":"M Van Brussel","year":"2008","unstructured":"Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net J, Helders PJ, Engelbert RH. Physical training in children with osteogenesis imperfecta. J Pediatr. 2008;152(1):111-116.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2007.06.029.","journal-title":"J Pediatr"},{"key":"2643_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13023-015-0362-2","volume":"10","author":"LL Tosi","year":"2015","unstructured":"Tosi LL, Oetgen ME, Floor MK, Huber MB, Kennelly AM, McCarter RJ, Rak MF, Simmonds BJ, Simpson MD, Tucker CA, McKiernan FE. Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis. 2015;10:146. https:\/\/doi.org\/10.1186\/s13023-015-0362-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2643_CR51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00198-018-4690-7","volume":"30","author":"T Swezey","year":"2019","unstructured":"Swezey T, Reeve BB, Hart TS, Floor MK, Dollar CM, Gillies AP, Tosi LL. Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community. Osteoporos Int. 2019;30(2):507\u201311. https:\/\/doi.org\/10.1007\/s00198-018-4690-7.","journal-title":"Osteoporos Int"},{"issue":"3","key":"2643_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajmg.a.20257","volume":"122A","author":"J Ablon","year":"2003","unstructured":"Ablon J. Personality and stereotype in osteogenesis imperfecta: behavioral phenotype or response to life\u2019s hard challenges? Am J Med Genet A. 2003;122A(3):201\u201314. https:\/\/doi.org\/10.1002\/ajmg.a.20257.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"2643_CR53","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1053\/apmr.2001.23889","volume":"82","author":"RH Engelbert","year":"2001","unstructured":"Engelbert RH, Gulmans VA, Uiterwaal CS, Helders PJ. Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability. Arch Phys Med Rehabil. 2001;82(7):943\u20138. https:\/\/doi.org\/10.1053\/apmr.2001.23889.","journal-title":"Arch Phys Med Rehabil"},{"issue":"5","key":"2643_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1023\/a:1012588218728","volume":"10","author":"JE Ware","year":"2001","unstructured":"Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Quality of life. 2001;10(5):405\u201320. https:\/\/doi.org\/10.1023\/a:1012588218728.","journal-title":"Quality of life"},{"issue":"5","key":"2643_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1023\/a:1012552211996","volume":"10","author":"C Taft","year":"2001","unstructured":"Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395\u2013404. https:\/\/doi.org\/10.1023\/a:1012552211996.","journal-title":"Qual Life Res"},{"issue":"10","key":"2643_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/00005650-200010000-00006","volume":"38","author":"MW Nortvedt","year":"2000","unstructured":"Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000;38(10):1022\u20138. https:\/\/doi.org\/10.1097\/00005650-200010000-00006.","journal-title":"Med Care"},{"issue":"1","key":"2643_CR57","first-page":"15","volume":"51","author":"M Bhandari","year":"2008","unstructured":"Bhandari M, Busse JW, Hanson BP, Leece P, Ayeni OR, Schemitsch EH. Psychological distress and quality of life after orthopedic trauma: an observational study. Can J Surg. 2008;51(1):15\u201322 (PMID: 18248701).","journal-title":"Can J Surg"},{"issue":"8","key":"2643_CR58","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 Antibody, in adults with x-linked hypophosphatemia: week 24 primary analysis. J Bone Mineral. 2018;33(8):1383\u201393. https:\/\/doi.org\/10.1002\/jbmr.3475.","journal-title":"J Bone Mineral"},{"key":"2643_CR59","unstructured":"Nct. The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta. https:\/\/clinicaltrialsgov\/show\/NCT01679080. (2012)"},{"issue":"1","key":"2643_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-019-1004-x","volume":"14","author":"LL Tosi","year":"2019","unstructured":"Tosi LL, Floor MK, Dollar CM, Gillies AP, Hart TS, Cuthbertson DD, Sutton VR, Krischer JP. Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study. Orphanet J Rare Dis. 2019;14(1):23. https:\/\/doi.org\/10.1186\/s13023-019-1004-x.","journal-title":"Orphanet J Rare Dis"},{"key":"2643_CR61","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3389\/fphar.2019.01200","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Ren M, Jia J, Tang M, Guo Y, Ni X, Shi T. Genotype-phenotype association analysis reveals new pathogenic factors for osteogenesis imperfecta disease. Front Pharmacol. 2019;10:1200. https:\/\/doi.org\/10.3389\/fphar.2019.01200.","journal-title":"Front Pharmacol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02643-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:04:08Z","timestamp":1677081848000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02643-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2643"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02643-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1788000\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}